On November 4, 2026, China’s National Health Commission (NHC) issued new Implementing Rules for the Regulation on the Administration of Human Genetic Resources (NHC Order No. 16). The rules took effect the same day. They repeal the 2023 implementing rules issued by the Ministry of Science and Technology (MOST Order No. 21).
The new rules narrow the scope of regulated HGR and Sino-foreign international collaborations, streamline clinical trial filings, and introduce risk-based enforcement. Penalties for violations remain unchanged. Multinational life sciences companies may benefit from the new rules when conducting their registration studies in China.
Key Changes
| Area | 2023 Rules | 2026 Rules |
| HGR materials and information (Art. 3) | The rules defined only HGR information and excluded clinical, imaging, protein, and metabolic data. Exclusions for serum, plasma, urine, and feces appeared only in MOST guidance. | The rules now define HGR materials as cell-containing materials, such as whole blood, tissue, semen, cerebrospinal fluid, and hair with follicles. They expressly exclude non-cellular secretions, body fluids, swabs, serum, plasma, urine, and feces. HGR information covers nucleic-acid sequence data and associated disease data, but not purely clinical, imaging, protein, or metabolic data. |
| Collection activity (Art. 16) | Collection approval applied to population studies of more than 3,000 cases, important genetic families, and specific regions. | Collection approval applies to population studies of more than 10,000 cases and to listed important genetic families and specific regions. Registrational drug and device trials remain exempt. The rules prohibit splitting collections to avoid approval. |
| Preservation activity (Art. 21) | Preservation meant storage for future scientific research. Only teaching and temporary post-testing storage were excluded. | Preservation means storage solely for scientific research. The rules also exclude storage primarily for clinical care or teaching, and storage to manufacture marketed drugs and devices. |
| Exploratory research in registrational trials (Arts. 27–28) | Exploratory research required separate international collaboration approval. | The clinical trial filing now covers exploratory research. The NHC confirms filings that involve no HGR information export on the same or next working day. |
| Journal and conference publication (Art. 40) | Publication was subject to the general prior report and backup process. | Submitting data to the National Bioinformation Center before publication or presentation counts as the prior report. |
| Clinical trial data shared abroad (Art. 41) | No separate report applied only where the collaboration agreement provided for joint use. | No separate prior report or backup is required if the approval or filing lists the foreign recipient. The same applies to public data and to trial data submitted to overseas drug regulators, if listed in the filing. |
| Risk-based enforcement (Arts. 56–57) | Inspections followed general annual and spot-check plans. | Regulators will prioritize entities penalized in the past three years, entities with uncorrected HGR risks, and entities on the serious dishonesty list. Regulators may also summon legal representatives for interviews. |
| “Foreign party unit” (Arts. 59–60) | The definition covered 50% ownership, sub-50% influence, and contractual control. Hong Kong and Macao entities under mainland control counted as Chinese parties. | The definition covers entities that offshore parties establish, actually control, or indirectly hold at 50% or more. The rules do not restate the sub-50% tests. Hong Kong and Macao entities under mainland control may act under the Chinese-party rules. Companies should confirm the control test against the official text. |
For our previous insights on China's regulation of human genetic resources, please see:
- China's State Council Publishes New Regulations on the Management of Human Genetic Resources (June 2019)
- China Unveils Implementing Rules on the Administration of Human Genetic Resources (June 2023)
Subscribe to Ropes & Gray Viewpoints by topic here.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.
